Plain-English translation of NCT07371338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new gene therapy called for people with advanced Parkinson's disease. The treatment is delivered as a single injection and works by using a modified virus to deliver genetic material that may help restore function in the brain. Researchers want to understand how safe this medication is, what dose works best, and whether it can help improve symptoms in people whose condition hasn't improved with existing treatments.
Standard Parkinson's medications stop working well for some patients, especially those in advanced stages of the disease. This trial exists because there is a need for new treatment options for people whose symptoms remain uncontrolled despite trying all available medicines.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this trial, you will receive a single injection of the study medication (either at a low or high dose). You will have regular visits to the research center where doctors will monitor your safety, check your symptoms, and run blood tests and scans to see how the treatment affects your body. The study is small (only 6 participants total) and conducted at a single center, so all care will happen in one location.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
South Korea